Novel pyrazole derivatives as anticancer and radiosensitizing agents

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 3, 2012, Pages 105-112

  Aly, H M ^a   El Gazzar, M G ^b  

^a Al Azhar University   (Egypt)

^b NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

Author keywords

anticancer; pyrazoles; radiosensitizing

Indexed keywords

1,5 DIMETHYL 4 (2 OXO 2 PHENYLETHYLAMINO) 2 PHENYL 1,2 DIHYDROPYRAZOL 3 ONE; 1,5 DIMETHYL 4 (4 NITROBENZYLIDENEAMINO) 2 PHENYL 1,2 DIHYDRO PYRAZOL 3 ONE; 2,3 DIMETHYL 1 PHENYL 1,2 DIHYDRO 4H PYRAZOLO[4,3 D] OXAZOLE 5(6 AH) THIONE; 4 AMINO 1,5 DIMETHYL 2 PHENYL 1,2 DIHYDROPYRAZOLE 3 THIONE; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; VINBLASTINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ADOLESCENT; ARTICLE; CANCER CELL; CELL KILLING; COLON CANCER; CONTROLLED STUDY; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; RADIATION EXPOSURE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GAMMA RAYS; HUMANS; INDICATORS AND REAGENTS; PYRAZOLES; RADIATION-SENSITIZING AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860641628     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297252     Document Type: Article

References (30)

1. Wilson W L, Bottiglieri N G. Phase I studies with pyrazole. Cancer Chemother. Rep: 1962; 21 137 141
2. Foley H T, Shnider B I, Gold G L et al. Phase I studies with pyrazole (NSC-45410). Cancer Chemother Rep: 1965; 44 45 48
3. Ausman R K, Nadler S, Moore G E. thiocarzolamide (NSC-45409): A phase I study. Cancer Chemother. Rep: 1963; 33 41 43
4. Bouabdallah I, M'Barek L A, Zyad A et al. New pyrazolic compounds as cytotoxic agents. A. Nat Prod Res: 2007; 21 298 302 (Pubitemid 46729925)
5. Havrylyuk D, Zimenkovsky B, Vasylenko O et al. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem: 2009; 44 1396 1404
6. Shaharyar M, Abdullah M M, Bakht M A et al. Pyrazoline bearing benzimidazoles: search for anticancer agent. Eur J Med Chem: 2010; 45 114 119
7. Lin R, Chiu G, Yu Y et al. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors. Bioorg Med Chem Lett: 2007; 17 4557 4581
8. Pevarello P, Brasca M G, Amici R et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem: 2004; 47 3367 3380 (Pubitemid 38746088)
9. Kry V, Canka P, Fry-sová I et al. 4-arylazo-3,5-diamino-1H- pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006; 49 6500 6509
10. Squires M S, Feltell R E, Wallis N G et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol. Cancer Ther: 2009; 8 324 332
11. Moravcová D, Kry-stof V, Havlícek L et al. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett: 2003; 13 2989 2992 (Pubitemid 37009743)
12. Regan J, Breitfelder S, Cirillo P et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem: 2002; 45 2994 3008 (Pubitemid 34721521)
13. Howard S, Berdini V, Boulstridge J A et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem: 2009; 52 379 388
14. Sawyer J S, Anderson B D, Beight D W et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem: 2003; 46 3953 3956 (Pubitemid 37122441)
15. Wasylyk C, Zheng H, Castell C et al. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res: 2008; 68 1275 1283 (Pubitemid 351346833)
16. Ghorab M M, Ragab F A, Heiba H I et al. Synthesis of some new pyrazole and pyrimidine derivatives carrying a sulfonamide moiety of expected antitumor activity and study of the synergistic effect of gamma-irradiation. Arzneimittelforschung: 2010; 60 01 48 55
17. Ghorab M M, Heiba H I, Hassan A A et al. Antimicrobial evaluation of novel pyrrole, pyrazole, pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives bearing sulfonamide moiety. J Am Sci: 2011; 7 01 1063 1073
18. Ghorab M M, Ragab F A, Heiba H I et al. Synthesis of Novel Pyrazole and Pyrimidine derivatives bearing Sulfonamide moiety as antitumor and radiosensitizing agents. Med Chem Res. 10.1007/s00044-011-9653-x
19. Aly H M. Synthesis and antitumor activity of some novel pyrazole and thienopyrimidine derivatives. Phosphorous. Sulfur and Silicon: 2010; 185 211
20. Aly H M. Novel Pyrrolidinone and Pyrazolo[1,5-a][1,3,5]triazine Derivatives Bearing Biologically Active Sulfamoyl Moiety as a New Class of Antitumor Agents. Monatsch. Chem: 2011; 142 935
21. Aly H M, Saleh N M, Elhady H A. Design and Synthesis of Some New Thiophene, Thienopyrimidine and Thienothiadiazine Derivatives of Antipyrine as Potential Antimicrobial Agents. Eur J Med Chem: 2011; 46 4566
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol. Methods: 1983; 65 55 63 (Pubitemid 14203433)
23. Vijayan P, Raghu C, Ashok G et al. Antiviral activity of medicinal plants of Nilgiris. Indian J Med Res: 2004; 120 24 29 (Pubitemid 39177430)
24. Dong H S, Wang B. The synthesis and crystal structure of new 3,6-bis[1-(4-ethoxyphenyl)-5-methyl-1,2,3- triazol-4-yl]-s-triazolo[3,4-b]-1,3, 4-thiadiazole. J Chem. Cryst: 2005; 35 01 61 65 (Pubitemid 40674563)
25. Pokhodylo N T, Matiychuk V S, Obushak M D. Synthesis of ethyl 4,5-disubstited 2-azido-3-thiophenecarboxylates and use in the synthesis of thieno[3,2-e][1,2,3-triazolo[1,5-a]pyrimidin-5(4H)-ones. Tetrahedron: 2009; 65 2678 2683
26. Noolvi M, Agrawal S, Patel H et al. Synthesis, antimicrobial and cytotoxic activity of novel azetidine-2-one derivatives of 1H-benzimidazole. Arabian Journal of Chemistry. 2011; 10.1016/j.arabjc.2011.02.011
27. Halve A K, Bhadauria D, Dubey R. N/C-4 substituted azetidin-2-ones: Synthesis and preliminary evaluation as new class of antimicrobial agents. Bioorg Med Chem Lett: 2007; 17 341 345 (Pubitemid 46073767)
28. Kumar A, Rajput C S, Bhati S K. Synthesis of 3-[4-(p-chlorophenyl)- thiazol-2-yl]-2-[(substituted azetidinone/thiazolidinone)-aminomethyl]-6- bromoquinazolin-4-ones as anti-inflammatory agent. Bioorg Med Chem: 2007; 15 3089 3096 (Pubitemid 46400456)
29. Nishimura Y. Rationale for chemoradiotherapy. Int Clin Oncol: 2004; 9 414 420
30. Bartelink H, Schellens JH M, Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumors. Eur J Cancer: 2002; 38 216 222 (Pubitemid 34136996)